May 31, 2020

The Niche

Knoepfler lab stem cell blog

Asterias

4 min read

Back in 2013, a half dozen years ago, I went out on a limb and made predictions for the stem cell field for 2020. These are different than my yearly predictions for the coming year (for instance, you can see my predictions made in 2018 for this year of 2019 here). As to my 2013 predictions, of course, it’s only 2019 and not yet 2020, but how are my old predictions looking at this point? I can’t be sure how they’ll look next year …Read More

3 min read

Australian stem cell biotech Mesoblast announced that it has received regenerative medicine advanced therapy (RMAT) designation from the U.S. FDA. This is very good news for the company and an encouraging development for the field. Interestingly, last month the FDA clarified that there is expanded RMAT designation that can include gene therapies too. At the Meeting on the Mesa in October, an FDA official reportedly presented data indicating that about 1/3 applications for RMATs were granted (see image below from Twitter). This recently announced RMAT …Read More

3 min read

Stem cell good news time…and more will be coming later this week. The stem cell and regenerative medicine world sometimes feels chaotic because so much is going on both on the positive and negative sides of things. There is a whirlwind of activity and developments, and a tendency sometimes within our arena to just avoid bad or complicated news. One mission of this blog is to try to cover the full spectrum of developments including difficult situations, but I also want to focus in …Read More

3 min read

It’s a difficult, but very important road to conclusively prove that an investigational stem cell therapy is both safe and effective in order to get final approval FDA or equivalents in other countries. For this reason, it is beneficial to highlight even small, but positive steps forward including encouraging pre-clinical data. Today I’m doing a review of stem cell therapy good news in the clinical path with a focus on biotechs in particular (in alphabetical order), but starting first with news from here at …Read More

3 min read

In December of each year I make a list of stem cell predictions for the coming year, and I made 20 such predictions for 2017 so I’m wondering how I’m doing so far on these now that it’s June. Below is my work-in-progress scorecard for these so far. Positive news from Asterias on trial for stem cell-based therapy for spinal cord injury. Status: Correct, trial looking encouraging. Upbeat news from ViaCyte on stem cell-based therapy trial for diabetes. Status: Correct, raising $10M and things looking promising. More positive news …Read More

1 min read

Enjoy! A brunch for the brain. News and links CBER Director Focuses on Flexibility to Advance Regenerative Medicines Lab-Grown Blood Stem Cells Produced at Last Transplanted stem cells become eggs in sterile mice Maryland fund awards $8.5 million for stem cell research Positively good news from Asterias for CIRM-funded stem cell clinical trial for spinal cord injury Sergio Canavero: Will His Head Transplants Roll? Century-old tumours offer rare cancer clues Papers Identification of hair shaft progenitors that create a niche for hair pigmentation (see Figure 2D above) Tip110 Deletion Impaired Embryonic and …Read More